CClinicalTrials.gg
RecruitingNCT06313242Updated Mar 19, 2024

Different Bowel Preparations in Magnetically Controlled Capsule Endoscopy

An interventional study of Polyethylene Glycol Electrolytes Powder (II) and Low residue diet in Magnetically Controlled Capsule Endoscopy and Bowel Preparation, sponsored by Qilu Hospital of Shandong University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-19.

Sponsored by Qilu Hospital of Shandong University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study aimed to compare the effects of bowel preparation methods of a normal diet for 1 day, a low residue diet for 1 day, and laxative bowel cleaning on the image quality of magnetically controlled capsule endoscopy, and to assess the rate of completion of the examination, small intestine transit time, lesion detection, patient tolerance, and safety of the three regimens.

02

Conditions studied

  • Magnetically Controlled Capsule Endoscopy
  • Bowel Preparation
03

In context

Lead sponsor

Qilu Hospital of Shandong University is the lead sponsor of 299 studies on the registry; 181 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age ≥ 18 years, male or female
  2. One of the following examination indications:

(1) Unexplained gastrointestinal bleeding; (2) Unexplained iron deficiency anaemia; (3) Suspected Crohn's disease or monitoring and directing treatment for Crohn's disease; (4) Suspected small bowel tumour; (5) Monitoring the development of small bowel polyposis syndrome; (6) Suspected or difficult to control malabsorption syndromes (e.g., celiac disease, etc.); (7) Detection of NSAID-associated small bowel mucosal damage; (8) Those with a clinical need to exclude small bowel disease.

Exclusion criteria

Exclusion Criteria:

  1. People who are ineligible for surgery or refuse to undergo any abdominal surgery (once the capsule is retained it cannot be removed surgically);
  2. Known or suspected gastrointestinal obstruction, stenosis, and fistula;
  3. People with implanted cardiac pacemakers or other electronic devices;
  4. People with swallowing disorders;
  5. Women during pregnancy;
  6. People who are unable or unwilling to provide informed consent.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
375 participants (estimated)

Study arms

  • Active comparator
    Laxatives arm

    Normal diet 1 day before the test, fasting and laxatives from 20:00 pm. The laxatives, Polyethylene Glycol Electrolytes Powder (II), should be prepared as a solution and taken as 2000 ml the night before the test and 1000 ml the following morning, within 2 hours and 1 hour, respectively.

    Drug: Polyethylene Glycol Electrolytes Powder (II)

  • Experimental
    Low residue diet arm

    Low residue diet 1 day before the test, fasting from 20:00 pm.

    Other: Low residue diet

  • Experimental
    Normal diet arm

    Normal diet 1 day before the test, fasting from 20:00 pm.

    Other: Normal diet

Interventions

  • DrugPolyethylene Glycol Electrolytes Powder (II)

    Polyethylene Glycol Electrolytes Powder (II) was used for bowel preparation.

    Also known as: laxatives for bowel preparation

  • OtherLow residue diet

    Low residue diet 1 day before the test, fasting from 20:00 pm.

  • OtherNormal diet

    Normal diet 1 day before the test, fasting from 20:00 pm.

06

What researchers measure

Primary outcomes

  1. Image quality of small intestine

    The small bowel cleanliness score and the small bowel bubble volume score were used to evaluate image quality.

    Time frame: 1 day (Upon completion of the examination)

Secondary outcomes

  1. Rate of completion of inspections

    The examination is considered complete when the capsule reaches the cecum.

    Time frame: 1 day (Upon completion of the examination)

  2. Small intestine transit time

    Time taken for the capsule to pass through the entire small intestine to reach the cecum.

    Time frame: 1 day (Upon completion of the examination)

  3. Lesion detection rate

    Proportion of cases with lesions relevant to the indication for examination or capable of explaining the patient's complaints or symptoms to the total number of cases.

    Time frame: 1 day (Upon completion of the examination)

  4. Patient tolerance

    Evaluated by completing a case report form based on the patient's personal feelings during the bowel preparation process.

    Time frame: 1 day (Upon completion of the examination)

  5. Rate of adverse events

    Patients were observed for adverse events (nausea, vomiting, bloating, etc.) and for capsule retention after examination.

    Time frame: 1 day (Upon completion of the examination)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Han Y, Liao Z, Li Y, Zhao X, Ma S, Bao D, Qiu M, Deng J, Wang J, Qu P, Jiang C, Jia S, Yang S, Ru L, Feng J, Gao W, Huang Y, Tao L, Han Y, Yang K, Wang X, Zhang W, Wang B, Li Y, Yang Y, Li J, Sheng J, Ma Y, Cui M, Ma S, Wang X, Li Z, Stone GW. Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy-Induced Gastrointestinal Injury. J Am Coll Cardiol. 2022 Jan 18;79(2):116-128. doi: 10.1016/j.jacc.2021.10.028. Epub 2021 Nov 6. PubMed 34752902 ↗
  • Wu TT, Zhang MY, Tan ND, Chen SF, Zhuang QJ, Luo Y, Xiao YL. Patients at risk for further examination with conventional gastroscopy after undergoing magnetically controlled capsule endoscopy. J Dig Dis. 2023 Oct;24(10):522-529. doi: 10.1111/1751-2980.13228. Epub 2023 Oct 3. PubMed 37681236 ↗
  • Jiang X, Qian YY, Liu X, Pan J, Zou WB, Zhou W, Luo YY, Chen YZ, Li ZS, Liao Z. Impact of magnetic steering on gastric transit time of a capsule endoscopy (with video). Gastrointest Endosc. 2018 Oct;88(4):746-754. doi: 10.1016/j.gie.2018.06.031. Epub 2018 Jul 11. PubMed 30005825 ↗
  • Kong QZ, Peng C, Li Z, Tian BL, Li YY, Chen FX, Zuo XL, Li YQ. Inadequate gastric preparation and its associated factors for magnetically controlled capsule endoscopy. Front Pharmacol. 2023 Aug 28;14:1184754. doi: 10.3389/fphar.2023.1184754. eCollection 2023. PubMed 37701026 ↗
  • Reumkens A, van der Zander Q, Winkens B, Bogie R, Bakker CM, Sanduleanu S, Masclee AAM. Electrolyte disturbances after bowel preparation for colonoscopy: Systematic review and meta-analysis. Dig Endosc. 2022 Jul;34(5):913-926. doi: 10.1111/den.14237. Epub 2022 Feb 23. PubMed 35037327 ↗
  • Gkolfakis P, Tziatzios G, Dimitriadis GD, Triantafyllou K. Meta-analysis of randomized controlled trials challenging the usefulness of purgative preparation before small-bowel video capsule endoscopy. Endoscopy. 2018 Jul;50(7):671-683. doi: 10.1055/s-0043-125207. Epub 2018 Feb 6. PubMed 29409067 ↗
  • Gomez-Reyes E, Tepox-Padron A, Cano-Manrique G, Vilchis-Valadez NJ, Mora-Bulnes S, Medrano-Duarte G, Chaires-Garza LG, Grajales-Figueroa G, Ruiz-Romero D, Tellez-Avila FI. A low-residue diet before colonoscopy tends to improve tolerability by patients with no differences in preparation quality: a randomized trial. Surg Endosc. 2020 Jul;34(7):3037-3042. doi: 10.1007/s00464-019-07100-6. Epub 2019 Sep 3. PubMed 31482360 ↗
  • Nguyen DL, Jamal MM, Nguyen ET, Puli SR, Bechtold ML. Low-residue versus clear liquid diet before colonoscopy: a meta-analysis of randomized, controlled trials. Gastrointest Endosc. 2016 Mar;83(3):499-507.e1. doi: 10.1016/j.gie.2015.09.045. Epub 2015 Oct 13. PubMed 26460222 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06313242
Lead sponsor
Qilu Hospital of Shandong University
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Mar 14, 2024
Primary completion
Feb 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Mar 19, 2024

Study contacts

Feixue Chen, Ph.D
Contact
chenfeixue@email.sdu.edu.cn
18560086108

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion